Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Poniard Pharmaceuticals reports net loss of $13.2M for fourth-quarter 2009

Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today reported financial results for the fourth quarter and year ended December 31, 2009.

8 Mar 2010

Rexahn Pharmaceuticals granted Japanese patent for Archexin

Rexahn Pharmaceuticals, Inc, a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the Japanese Patent Office has issued a patent for its novel anti-cancer compound, Archexin®.

8 Mar 2010

Positive Phase 2 data from Nektar Therapeutics' NKTR-102 study in women with platinum-resistant ovarian cancer

Nektar Therapeutics today announced preliminary progression-free survival data from the first stage of a two-stage Phase 2 clinical study evaluating single-agent treatment with NKTR-102 in women with platinum-resistant ovarian cancer. In the first stage of the study, 39 patients were enrolled with platinum-resistant disease and were evaluable for the secondary endpoint of progression-free survival (PFS).

8 Mar 2010

Luminetx, Alliance Medical sign exclusive national sales distribution agreement

Luminetx®, a division of Christie Medical Holdings, Inc. and recently acquired by Christie Digital Systems USA, Inc., has signed an exclusive national sales distribution agreement with New Alliance of Independent Medical Distributors, Inc., DBA Alliance Medical. The agreement, effective last month, aligns the medical device company with Alliance Medical, the nation’s largest consortium of specialty medical sales distribution companies for intravenous devices, with comprehensive access to the U.S. acute, oncology and home health markets.

8 Mar 2010

DiagnoCure: Global studies confirm clinical utility of PROGENSA PCA3 test

DiagnoCure, Inc., a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, announced that the clinical utility of the PROGENSA(R) PCA3 test, developed and commercialized by its partner Gen-Probe, was confirmed in two large worldwide studies, conducted in a subset of patients in GlaxoSmithKline's REDUCE trial of dutasteride. The results demonstrate that PCA3 can help determine whether men suspected of having prostate cancer should undergo a repeat biopsy and can predict the risk of having an aggressive cancer.

8 Mar 2010

Necessity of repeat biopsy in suspected prostate cancer: Gen-Probe's PROGENSA PCA3 assay can help determine

Gen-Probe's PROGENSA® PCA3 assay can help determine whether men suspected of having prostate cancer should undergo a repeat biopsy, according to data from the two largest studies to date of the molecular urine test. The studies were presented last week at the American Society of Clinical Oncology's (ASCO) Genitourinary (GU) Cancers Symposium in San Francisco.

8 Mar 2010

NerPharMa facility receives FDA approval to manufacture CTI's drug pixantrone

Cell Therapeutics, Inc. today announced that the U.S. Food and Drug Administration has completed its inspection of the facility at NerPharMa (a pharmaceutical manufacturing company belonging to Nerviano Medical Sciences Srl, in Nerviano, Italy), which manufactures the CTI's drug pixantrone and has found the site in compliance and acceptable for continued manufacturing of the drug product.

8 Mar 2010

Breast cancer patients with early stage disease may not benefit from radiation after mastectomy

Breast cancer patients with early stage disease that has spread to only one lymph node may not benefit from radiation after mastectomy, because of the low present-day risk of recurrence following modern surgery and systemic therapy, a finding that could one day change the course of treatment for thousands of women diagnosed each year, according to researchers at The University of Texas M. D. Anderson Cancer.

7 Mar 2010

Roche, OrbiMed, McKinsey announce fifteen finalists of SEED Competition

Roche, OrbiMed, and McKinsey announced fifteen finalists of the SEED Competition at the SEED Finalist Coaching Day event in Shanghai’s Zhangjiang Hi-Tech Park on March 2, 2010. The event was managed and presented by ChinaBio® Accelerator. The finalists will go on to compete for the grand prize of RMB 300,000 to be presented at the SEED Final Competition and Award Ceremony in Shanghai on April 23, 2010.

6 Mar 2010

ISSP model can help payers realize oncology savings of $16.3M for every 10,000 Medicare beneficiaries

New Century Infusion Solutions, Inc. (NCIS), the first Oncology Benefit Management (OBM) company, is pleased to announce the publication of a white paper by the Lewin Group: “Medicare Cancer Care Coordination Using The Integrated Single Specialty Provider (ISSP) Model.” The report estimates that over a 10-year horizon, a payer could realize oncology savings of “$16.3 million for every 10,000 Medicare beneficiaries included in the ISSP arrangement.”

6 Mar 2010

Research group performs randomized study to evaluate efficacy of ICCBco in treatment of lung lesions

To evaluate efficacy of Calculus Bovis compound preparation (ICCBco) in the treatment of lung lesions in portal hypertensive rabbits with schistosomiasis as the experimental animal model, a research group in China performed a randomized, double-blind, controlled trial to observe pathological changes and pathological effect mechanism of expression of fibronectin and laminin in the lung tissue of portal hypertensive rabbits with schistosomiasis.

6 Mar 2010

Increased risk of colorectal cancer associated with obesity may be restricted to tumors that have no MSI

The increased risk of colorectal cancer associated with obesity may be largely restricted to tumors that have no or low microsatellite instability (MSI), a common condition in most colorectal cancers, according to a new study published online March 8 in the Journal of the National Cancer Institute.

6 Mar 2010

US Oncology honored with FORTUNE magazine's World's Most Admired Companies distinction

US Oncology, Inc., the leading oncology services company uniting the nation's largest cancer treatment and research network to expand patient access to high-quality, cost-effective cancer care and advance the science of cancer care, has been named to FORTUNE magazine's World's Most Admired Companies list for 2010.

6 Mar 2010

Research Roundup: Childhood obesity, insurance coverage in cancer trials, hospitals stays and need for nursing homes

Health Affairs this month is devoted to the topic of childhood obesity, with the first study of the group - National, State, And Local Disparities In Childhood Obesity - pointing out that "new data from the 2007 National Survey of Children's Health show that the percentage of children ages 10-17 who are overweight ... remained stable, while the national prevalence of obesity (BMI in the ninety-fifth percentile and higher) grew significantly, from 14.8 percent in 2003 to 16.4 percent in 2007.

6 Mar 2010

Postoperative complications more likely to occur at low-volume institutions

The frequency of post-operative complications following surgery for liver cancer is associated with a hospital having a low volume of liver surgery. Investigators at The Cancer Institute of New Jersey (CINJ) are presenting that finding at the 63rd Annual Society of Surgical Oncology Symposium taking place this week in St. Louis. CINJ is a Center of Excellence of UMDNJ-Robert Wood Johnson Medical School.

6 Mar 2010

Inpatient integrative medicine program can have significant impact on pain: Study

Non-traditional therapies relieve pain among a wide range of hospitalized patients as much as 50 percent, according to a first-of-a-kind study in the Journal of Patient Safety.

6 Mar 2010

Poniard Pharmaceuticals' picoplatin Phase 2 study in metastatic CRPC: Positive results

Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today announced the presentation of positive final data, including survival data, from the Company's Phase 2 clinical trial of picoplatin as a first-line therapy in men with metastatic castration-resistant (hormone-refractory) prostate cancer (CRPC). The results were presented in a General Poster Session today at the 2010 American Society of Clinical Oncology's Genitourinary Cancers Symposium in San Francisco, CA.

6 Mar 2010

Saladax Biomedical announces closing of $8.4M Series C Preferred offering

Saladax Biomedical, Inc. announced today the close of an $8.4 million Series C Preferred offering led by Excel Venture Management of Boston. Participants included Golden Seeds LLC, Ben Franklin Technology Partners, and the Life Sciences Greenhouse of Central Pennsylvania, as well as a number of angel investors. The funding will be used to accelerate product development and expand clinical support of Saladax’s MYCARE™ line of diagnostic tests, which measure blood levels of cancer and Central Nervous System (CNS) disorder drugs, providing physicians with guidance to personalize patient dosing for optimal efficacy.

5 Mar 2010

Life Technologies, TGen, US Oncology collaborate to sequence genomes of triple negative breast cancer patients

Life Technologies Corporation today announced that it is collaborating with the Translational Genomics Research Institute and US Oncology to sequence the genomes of 14 patients afflicted with triple negative breast cancer whose tumors have progressed despite multiple other therapies.

5 Mar 2010

Predictive Biosciences to present its novel MADR approach during 2010 GU Symposium

Predictive Biosciences today announced that the Company will be presenting its novel Multi-Analyte Diagnostic Readout approach to the development of a non-invasive, urinary biomarker based assay for the detection of bladder cancer during the 2010 Genitourinary Cancers Symposium, being held March 5-7 in San Francisco.

5 Mar 2010

Oncology News and Research

Further Reading

Poniard Pharmaceuticals reports net loss of $13.2M for fourth-quarter 2009

Rexahn Pharmaceuticals granted Japanese patent for Archexin

Positive Phase 2 data from Nektar Therapeutics' NKTR-102 study in women with platinum-resistant ovarian cancer

Luminetx, Alliance Medical sign exclusive national sales distribution agreement

DiagnoCure: Global studies confirm clinical utility of PROGENSA PCA3 test

Necessity of repeat biopsy in suspected prostate cancer: Gen-Probe's PROGENSA PCA3 assay can help determine

NerPharMa facility receives FDA approval to manufacture CTI's drug pixantrone

Breast cancer patients with early stage disease may not benefit from radiation after mastectomy

Roche, OrbiMed, McKinsey announce fifteen finalists of SEED Competition

ISSP model can help payers realize oncology savings of $16.3M for every 10,000 Medicare beneficiaries

Research group performs randomized study to evaluate efficacy of ICCBco in treatment of lung lesions

Increased risk of colorectal cancer associated with obesity may be restricted to tumors that have no MSI

US Oncology honored with FORTUNE magazine's World's Most Admired Companies distinction

Research Roundup: Childhood obesity, insurance coverage in cancer trials, hospitals stays and need for nursing homes

Postoperative complications more likely to occur at low-volume institutions

Inpatient integrative medicine program can have significant impact on pain: Study

Poniard Pharmaceuticals' picoplatin Phase 2 study in metastatic CRPC: Positive results

Saladax Biomedical announces closing of $8.4M Series C Preferred offering

Life Technologies, TGen, US Oncology collaborate to sequence genomes of triple negative breast cancer patients

Predictive Biosciences to present its novel MADR approach during 2010 GU Symposium

eBook: Liquid biopsy in cancer research eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News